Limitations of Chromogranin A in clinical practice
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
CONTEXT: Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool. METHODS: Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay. RESULTS: The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions. CONCLUSION: Serum CgA is not helpful for the first-line diagnosis of NEN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
O’Toole, D., Grossman, A., Gross, D., Delle Fave, G., Barkmanova, J., O’Connor, J., Pape, U.-F., & Plöckinger, U. (2009) · Neuroendocrinology · doi:10.1159/000225948 · Cited by 268
Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana, D., Nori, F., Piscitelli, L., Morselli-Labate, A. M., Pezzilli, R., Corinaldesi, R., & Tomassetti, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.1535 · Cited by 248
Proton pump inhibitors and gastric neoplasia: Figure 1
Kuipers, E. J. (2006) · Gut · doi:10.1136/gut.2005.090514 · Cited by 115
Vezzosi, D., Walter, T., Laplanche, A., Raoul, J. L., Dromain, C., Ruszniewski, P., d'Herbomez, M., Guigay, J., Mitry, E., Cadiot, G., et al. (2011) · The International Journal of Biological Markers · doi:10.5301/jbm.2011.8327 · Cited by 43 · cited 1×
“A recent study performed by Vezzosi et al. (2011) assessed the accuracy of serum CgA as marker of morphological evolution of disease in an population of well-differentiated gastroenteropancreatic NEN.”
Method
Cited by
Consensus on biomarkers for neuroendocrine tumour disease
Oberg, K., Modlin, I. M., De Herder, W., Pavel, M., Klimstra, D., Frilling, A., Metz, D. C., Heaney, A., Kwekkeboom, D., Strosberg, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00186-2 · Cited by 283
Marotta, V., Zatelli, M. C., Sciammarella, C., Ambrosio, M. R., Bondanelli, M., Colao, A., & Faggiano, A. (2018) · Endocrine-Related Cancer · doi:10.1530/erc-17-0269 · Cited by 161
Self-citationKnigge, U., Capdevila, J., Bartsch, D. K., Baudin, E., Falkerby, J., Kianmanesh, R., Kos-Kudla, B., Niederle, B., Nieveen van Dijkum, E., O'Toole, D., et al. (2017) · Neuroendocrinology · doi:10.1159/000458155 · Cited by 136
Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase
Braga, F., Ferraro, S., Mozzi, R., Dolci, A., & Panteghini, M. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2012.09.005 · Cited by 49
Jilesen, A. P. J., Busch, O. R. C., van Gulik, T. M., Gouma, D. J., & Nieveen van Dijkum, E. J. M. (2014) · Digestive Surgery · doi:10.1159/000370007 · Cited by 26
Metadata
- Authors
- Marotta, V., Nuzzo, V., Ferrara, T., Zuccoli, A., Masone, M., Nocerino, L., Del Prete, M., Marciello, F., Ramundo, V., Lombardi, G., Vitale, M., Colao, A., & Faggiano, A.
- Venue
- Biomarkers
- Publisher
- Informa UK Limited
- Published
- 2012-02-06
- Volume
- 17
- Issue
- 2
- Pages
- 186-191
- ISSN
- 1354-750X (ISSN-L)
- 1366-5804
- OpenAlex
- W2028618819
- Cited by
- 61
- References
- 4
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.